ALLG clinical trial HD10: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD

Trial Lead: Professor Mark Hertzberg.

HD10 is an international, prospective, randomised and open-label Phase III trial.

The aim of this trial is to prove that the new chemotherapy regimen BrECADD, is non-inferior to BEACOPP as first line treatment in advanced stage classical Hodgkin lymphoma, each followed by radiotherapy to PET-positive residual lesions greater than or equal to 2.5cm, to improve PFS rates.

The co-primary endpoint for this trial is the rate of serious treatment-related morbidity- “TRMorbidity”. Secondary Endpoints are Overall Survival, Tumour response (final treatment outcome), Infertility rate at 1 year, Secondary Malignancies.

The clinical trial will recruit approximately 90 patients across 16 Australasian sites. The timeline for the recruitment of patients is 2018 to mid-2020.

For more information on current clinical trials, visit the ALLG website.